Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02014090
Other study ID # 177/07
Secondary ID
Status Completed
Phase N/A
First received April 5, 2011
Last updated December 11, 2013
Start date March 2008
Est. completion date October 2011

Study information

Verified date December 2013
Source University Hospital Inselspital, Berne
Contact n/a
Is FDA regulated No
Health authority Switzerland: Ethikkommission
Study type Interventional

Clinical Trial Summary

The purpose of this study in humans with stable coronary artery disease (CAD) treatable by percutaneous intervention (PCI) is to evaluate the efficacy of Enhanced External Counterpulsation (EECP) with regard to coronary collateral growth.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date October 2011
Est. primary completion date October 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age > 18 years, written informed consent to participate in the study

Exclusion Criteria:

- 1. Pregnancy (serum ß-HCG<2 IU/l for all female volunteers)

Baseline History:

1. Endurance exercise 5 days before and the days between the exams

2. History of cardiovascular disease or surgery, including arterial hypertension, Raynaud phenomenon, recurrent migraine, or any cardiac rhythm disorder

3. History of metabolic disorder, particularly diabetes mellitus

4. History of respiratory, renal, hepatic or cerebral disease

5. Allergic reactions to Luminity or its components

6. Cardiovascular medication

7. Illness characterized by acute phase response

8. Anaemia with haemoglobin levels < 110 g/L

Baseline Physical Examination:

1. Peripheral artery disease

Baseline Echocardiogram:

1. Valvular heart disease

2. Aortic aneurysm (any abnormality of ascending aorta, aortic arch or descending aorta)

3. Intra- or extracardiac shunt

4. Systolic or diastolic left ventricular (LV) dysfunction

5. LV-hypertrophy

6. Pulmonary arterial hypertension

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


Intervention

Other:
Hemodynamic and biological measurements
by MCE, PWA, Doppler, Multiplex, FACS

Locations

Country Name City State
Switzerland University Hospital Bern

Sponsors (1)

Lead Sponsor Collaborator
University Hospital Inselspital, Berne

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Myocardial Blood Flow (MBF) measurement by Myocardial Contrast Echocardiography (MCE) During ECP respectively Bicycle Exercise, expected to be on average 90 minutes No
Secondary Puls Wave Velocity Analysis At baseline & post intervention, expected to be on average 90 minutes No